Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) stock from Neutral to Sell, adjusting the price target downward to $12.00 from the previous $15.00. According to InvestingPro ...
6d
A look at how Kennedy convinced Sen. Cassidy, a doctor and vaccination advocate, that he should become health secretary.
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback